Abstract |
Using a novel monoclonal anti-pan human leukocyte antigen (HLA) class I heavy chain antibody (EMR 8-5) reacting with paraffin-embedded sections, we examined the prognostic significance of HLA class I molecules in muscle-invasive bladder cancer patients who underwent radical cystectomy. Immunohistochemical staining for HLA class I molecules with monoclonal antibody EMR 8-5 was performed on specimens from 65 clinically muscle-invasive bladder cancer patients who underwent radical cystectomy and pelvic lymph node dissection without neoadjuvant chemotherapy. We analyzed the clinicopathological and prognostic significance of HLA class I expression. Immunohistochemical analysis revealed HLA class I down-regulation in 22 (33.8%) invasive bladder cancers. This down-regulation had no correlation with clinicopathological parameters such as pathologic stage, nodal status, and grade. The recurrence-free survival of patients with HLA class I-positive tumors was significantly better than that of those with down-regulation (log rank, P = 0.0337). Multivariate analysis revealed that HLA class I expression was a significant factor influencing the recurrence-free survival of bladder cancer patients after cystectomy (P = 0.0155). Our data demonstrate that HLA class I down-regulation in tumor cells was clearly observed in about one-third of the patients. HLA class I expression could be a prognostic marker for muscle-invasive bladder cancer patients after cystectomy.
|
Authors | Ichiya Homma, Hiroshi Kitamura, Toshihiko Torigoe, Toshiaki Tanaka, Eiji Sato, Yoshihiko Hirohashi, Naoya Masumori, Noriyuki Sato, Taiji Tsukamoto |
Journal | Cancer science
(Cancer Sci)
Vol. 100
Issue 12
Pg. 2331-4
(Dec 2009)
ISSN: 1349-7006 [Electronic] England |
PMID | 19751235
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Adult
- Aged
- Cystectomy
- Down-Regulation
- Female
- Genes, MHC Class I
- Humans
- Male
- Middle Aged
- Neoplasm Invasiveness
- T-Lymphocytes, Cytotoxic
(immunology)
- Urinary Bladder Neoplasms
(immunology, mortality, pathology, surgery)
|